↩ Compound referenceLongevity

FOXO4-DRI

10mg
Reported, not recommended

Every figure below is transcribed from published literature (peptideprotocolportal.com, compiled 2026-09-29). None of it is a recommendation, a protocol, or a target, and none of it was written here. Whether any of it applies to a person is a question for a licensed clinician — who this is for explains why.

What the source says not to do

Quoted word for word from the notes column. Nothing here is paraphrased, and nothing has been added.

  • Not for continuous use

As reported

The single row the source carries for this compound.

Reported dose, frequency and route for FOXO4-DRI, by vial size.
VialDoseFrequencyRoute
10mg5mg2-3 days per cycle, every 1-3 monthsSubQ

The source's own notes

Reproduced in full, including the parts that are description rather than caution. Trimming this column for layout would remove its harm-reduction payload.

Senolytic peptide. Clears senescent cells. Not for continuous use


Before anything else

A compound's paperwork is the part you can actually verify. Reading a Certificate of Analysis and what a COA cannot tell you cover both halves of that, and inspecting a vial on arrival covers what to check before a vial is opened at all.

Same category

Compounds grouped with this one

Cerluten A-5 (Oral)
Oral Cap
Epithalon
10mg · 50mg